Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$2.17B |
| 2 |
Microsoft
MSFT
|
+$619M |
| 3 |
Apple
AAPL
|
+$377M |
| 4 |
Booking.com
BKNG
|
+$319M |
| 5 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$270M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.48B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$896M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$599M |
| 4 |
Citigroup
C
|
+$467M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$430M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 91.29% |
| 2 | Technology | 2.06% |
| 3 | Consumer Discretionary | 1.55% |
| 4 | Financials | 1.15% |
| 5 | Healthcare | 0.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11751
CALL
Invivyd
IVVD
$284M
| $16.4K | ﹤0.01% |
10,900
-10,400
| -49% | -$28.9K |
|
11752
Jasper Therapeutics
JSPR
$23.3M
| $16.3K | ﹤0.01% |
+3,437
| New | +$23K |
|
11753
Real REMAX Group Inc. Common Stock
REAX
$460M
| $16.3K | ﹤0.01% |
+1,553
| New | +$21K |
|
11754
PUT
Aterian
ATER
$7.03M
| $16.2K | ﹤0.01% |
1,758
-21,825
| -93% | -$273K |
|
|
ARBK
11755
Argo Blockchain
ARBK
$42M
| $16.2K | ﹤0.01% |
69
+18
| +35% | +$4.99K |
|
11756
Usio Inc
USIO
$78.9M
| $16.2K | ﹤0.01% |
+10,103
| New | +$20.2K |
|
11757
Polar Power
POLA
$5.98M
| $16.1K | ﹤0.01% |
1,779
-12
| -0.7% | -$172 |
|
11758
Professional Diversity Network
IPDN
$1.78M
| $16K | ﹤0.01% |
+775
| New | +$12.9K |
|
|
ISPO
11759
CALL
DELISTED
Inspirato
ISPO
| $15.8K | ﹤0.01% |
665
-19,965
| -97% | -$756K |
|
|
MARK
11760
DELISTED
Remark Holdings, Inc.
MARK
| $15.7K | ﹤0.01% |
14,235
+4,572
| +47% | +$11.2K |
|
11761
PUT
Celularity
CELU
$45.7M
| $15.6K | ﹤0.01% |
1,210
-3,220
| -73% | -$59.4K |
|
11762
PUT
Katapult Holdings
KPLT
$483M
| $15.6K | ﹤0.01% |
648
-9,320
| -93% | -$223K |
|
|
TALK
11763
DELISTED
Talkspace
TALK
| $15.5K | ﹤0.01% |
+25,450
| New | +$19.6K |
|
11764
GlucoTrack
GCTK
$225K
| $15.5K | ﹤0.01% |
+2
| New | +$20.5K |
|
11765
Oragenics
OGEN
$2.37M
| $15.4K | ﹤0.01% |
+82
| New | +$28.9K |
|
11766
Inhibikase Therapeutics
IKT
$336M
| $15.3K | ﹤0.01% |
+5,109
| New | +$20.3K |
|
|
YVR
11767
DELISTED
Liquid Media Group Ltd. Common Shares
YVR
| $15.2K | ﹤0.01% |
21,522
+13,684
| +175% | +$14.1K |
|
|
CFRX
11768
DELISTED
ContraFect Corporation
CFRX
| $15.1K | ﹤0.01% |
1,970
+1,243
| +171% | +$14.4K |
|
|
AMPE
11769
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $15K | ﹤0.01% |
3,330
+2,943
| +760% | +$19K |
|
11770
Boxlight
BOXL
$4.37M
| $15K | ﹤0.01% |
33
+9
| +38% | +$5.72K |
|
|
BCEL
11771
PUT
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $15K | ﹤0.01% |
+18,700
| New | +$23.8K |
|
11772
PUT
Ouster
OUST
$2.5B
| $14.8K | ﹤0.01% |
1,720
-3,360
| -66% | -$36.6K |
|
11773
CALL
Westwater Resources
WWR
$74.3M
| $14.8K | ﹤0.01% |
18,700
+6,300
| +51% | +$6.69K |
|
|
NYMX
11774
DELISTED
Nymox Pharmaceutical Corp
NYMX
| $14.8K | ﹤0.01% |
49,698
+14,482
| +41% | +$5.24K |
|
11775
Lipocine
LPCN
$17.9M
| $14.7K | ﹤0.01% |
2,177
+118
| +6% | +$860 |
|
Similar funds
Jeff Yass's Q4 2022 Portfolio in Review
As of Q4 2022, Jeff Yass held 14,748 positions worth $395B, up 2.2% from $387B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jeff Yass's Q4 2022 filing shows 1,670 new, 4,598 increased, 5,764 reduced and 2,486 closed positions. Its largest new stake was Vanguard FTSE All-World ex-US ETF: 2,560,357 shares worth $128M. The largest sale was Amazon, an estimated $1.48B.
By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, down from 92% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q4 2022 buy was Vanguard FTSE All-World ex-US ETF: 2,560,357 shares worth $128M.
- Jeff Yass added most to Tesla in Q4 2022, an estimated $2.17B increase.
- Jeff Yass's biggest Q4 2022 reduction was Amazon, cutting an estimated $1.48B.
- Jeff Yass fully exited Twitter, Inc. in Q4 2022, selling an estimated $76M.
- Jeff Yass's ten largest holdings make up 27% of its $395B portfolio in Q4 2022.
- Jeff Yass opened 1,670 new positions and closed 2,486 in Q4 2022.
- Jeff Yass's portfolio value rose 2.2% quarter-over-quarter to $395B.
Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.